Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT04752696
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
41 participants
INTERVENTIONAL
2021-05-25
2024-12-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU
The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m\^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m\^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m\^2 leucovorin and 2400 mg/m\^2 fluorouracil (5-FU).
Onvansertib
Oral capsule
Nanoliposomal irinotecan
Intravenous infusion
Leucovorin
Intravenous infusion
Fluorouracil
Intravenous infusion
Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU
Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m\^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m\^2 leucovorin and 2400 mg/m\^2 fluorouracil (5-FU).
Onvansertib
Oral capsule
Nanoliposomal irinotecan
Intravenous infusion
Leucovorin
Intravenous infusion
Fluorouracil
Intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Onvansertib
Oral capsule
Nanoliposomal irinotecan
Intravenous infusion
Leucovorin
Intravenous infusion
Fluorouracil
Intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has received 1 prior gemcitabine-based chemotherapy as first line therapy for metastatic disease. Progression after completion of neoadjuvant or adjuvant therapy of \< 6 months in duration is considered 1 line of therapy for metastatic disease
* Has measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques or as \> 10 mm with spiral computed tomography (CT) scan
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
* Must be willing and able to undergo a tissue biopsy at screening; participants who, in the opinion of the investigator, do not have tissue that is accessible for biopsy are excepted from this criterion
* Women of childbearing potential: (defined as not post-menopausal for 12 months or no previous surgical sterilization) and fertile men must agree to use adequate contraception for the duration of study participation and for 4 months after the last dose of nal-IRI. Male subjects must agree to refrain from sperm donation during the study and for 4 months after the last dose of nal-IRI
* Ability to understand and the willingness to sign a written informed consent document. Signed informed consent form must be obtained prior to initiation of study evaluations and/or activities
* International Normalized Ratio (INR) \< 1.5 unless on warfarin
* Participants with prior malignancy and who were treated with no evidence of active disease more than 2 years from initial diagnosis are eligible
* Age ≥ 18 years
* Participants must have adequate organ and bone marrow function
Exclusion Criteria
* Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3 months of initiation of therapy
* History of interstitial pneumonitis or interstitial lung disease
* Participants with microsatellite instability-high (MSI-H) tumors with no prior immune checkpoint inhibitor exposure
* Pregnancy or lactation
* Participant has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
* QT interval with Fridericia's correction (QTcF) \> 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation, (eg, medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility
* Planned concomitant use of medications known to prolong the QT/QTc interval
* Participant has undergone major surgical resection within 4 weeks prior to enrollment
* Participant received radiotherapy, surgery, chemotherapy, or an investigational therapy within 2 weeks prior to study entry
* Participant has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the participant to receive an experimental research drugs
* Serious psychiatric or medical conditions that could interfere with treatment
* Major bleeding in the last 4 weeks
* More than 1 prior chemotherapy regimen administered in the metastatic setting
* Unable or unwilling to swallow oral medication
* Use of strong CYP3A4 or UGT1A1 inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who are able to switch to alternate therapy are not excluded. Inhibitors should be stopped at least one week prior to the first dose of protocol therapy and inducers should be stopped at least two weeks prior to initiation of protocol therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cardiff Oncology
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Phoenix
Phoenix, Arizona, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
University of Kansas Medical Center
Westwood, Kansas, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRDF-001
Identifier Type: -
Identifier Source: org_study_id